Replies to post #305644 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

At technical conferences it's normal to have the scientists make the presentations, not the management. In this case the lead clinician, and developer of the vaccine is leading the presentation, which is completely appropriate.

After SNO I would expect management to attend a variety of Investor's Conferences and present a corporate presentation on the opportunity the company presents to investors. I believe the share price will be substantially higher and we'll be invited to major conferences, like the J.P. Morgan Healthcare Conference in early January. That's probably the biggest such conference annually.

Gary

[anders2211]

I cant get any more clear then this:

LTBK-02 - Phase III Clinical Trial to Test the Safety and Efficacy of Autologous Tumor Lysate-Loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma

This is odd:

Participants should be aware of the following financial/non-financial relationships:
Linda M. Liau, MD, PhD: Arbor Pharmaceuticals (Consultant)JW Creagene (Consultant)
Marnix Bosch, MBA, PhD: No disclosure data submitted.

MB
Marnix Bosch, MBA, PhD

Northwest Biotherapeutics

I do not have any relevant financial / non-financial relationships with any proprietary interests.

https://www.eventscribe.com/2020/SNO/fsPopup.asp?efp=S0taQ1hBSFkxMTYzNQ&PresentationID=772799&rnd=0.2810788&query=Dcvax&mode=presinfo